Clearside Biomedical, Inc. (CLSD) Research

Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to pioneering novel drug delivery methods to the posterior segment of the eye via the suprachoroidal space. Its commercial product, XIPERE, is a triamcinolone acetonide suprachoroidal injectable suspension designed for treating uveitis macular edema. The company's development pipeline also features CLS-AX, an axitinib injectable suspension administered into the suprachoroidal space, which is currently undergoing Phase 1/2a clinical trials. Additionally, they are advancing CLS-301, an integrin inhibitor suspension aimed at addressing diabetic macular edema and macular degeneration. Clearside maintains strategic partnerships with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Established in 2011, Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.

Market snapshot

Symbol
CLSD
Price
$0.41
Day change
0.00%
Market cap
$1.4M
P/E ratio
-0.05x
52-week range
0.31-17.1
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Allarity Therapeutics, Inc. (ALLR)
  • CASI Pharmaceuticals, Inc. (CASI)
  • Cingulate Inc. (CING)
  • Entero Therapeutics, Inc. (ENTO)
  • Kairos Pharma, Ltd. (KAPA)
  • Lexaria Bioscience Corp. (LEXX)
  • Lisata Therapeutics, Inc. (LSTA)
  • MetaVia Inc. (MTVA)

Recent insider activity

  • WHITMORE BRADFORD T — P-Purchase (50000 shares) on 2020-08-13
  • WHITMORE BRADFORD T — P-Purchase (300000 shares) on 2020-08-12

Open Clearside Biomedical, Inc. (CLSD) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.